Lunai Bioworks (LNAI) Total Non-Current Liabilities (2012 - 2026)
Lunai Bioworks (LNAI) posted quarterly Total Non-Current Liabilities of $131316.0 for Q1 2026, down 73.61% year-over-year from $497629.0 in Q1 2025, and down 38.54% quarter-over-quarter from $213657.0 in Q4 2025.
Lunai Bioworks (LNAI) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Lunai Bioworks' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $131316.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 73.61% year-over-year to $131316.0; the TTM figure through Mar 2026 stood at $131316.0 (down 73.61% YoY), while the FY2025 annual figure was $424547.0, down 49.6% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $131316.0, down from $213657.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $22.8 million in Q1 2024, with the low at $131316.0 in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $720801.0 (2023), against an average of $3.0 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 2650.77% in 2024, then sank 97.82% in 2025.
- Lunai Bioworks' Total Non-Current Liabilities stood at $2.1 million in 2022, then tumbled by 68.1% to $664218.0 in 2023, then gained by 1.5% to $674200.0 in 2024, then slumped by 68.31% to $213657.0 in 2025, then plunged by 38.54% to $131316.0 in 2026.
- Business Quant data shows LNAI's Total Non-Current Liabilities at $131316.0 in Q1 2026, $213657.0 in Q4 2025, and $278963.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 131,316.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131,316.00 |
| Dec 31, 2025 | 213,657.00 |
| Sep 30, 2025 | 278,963.00 |
| Jun 30, 2025 | 424,547.00 |
| Mar 31, 2025 | 497,629.00 |
| Dec 31, 2024 | 674,200.00 |
| Sep 30, 2024 | 710,260.00 |
| Jun 30, 2024 | 842,389.00 |
| Mar 31, 2024 | 22.81 Mn |
| Dec 31, 2023 | 664,218.00 |
| Sep 30, 2023 | 720,801.00 |
| Jun 30, 2023 | 775,587.00 |
| Mar 31, 2023 | 829,213.00 |
| Dec 31, 2022 | 2.08 Mn |
| Sep 30, 2022 | 5.59 Mn |
| Jun 30, 2022 | 5.56 Mn |
| Mar 31, 2022 | 8.55 Mn |
| Dec 31, 2021 | 8.49 Mn |
| Sep 30, 2021 | 17.09 Mn |
| Jun 30, 2021 | 13.06 Mn |